Prescribing information

LUTATHERA® (lutetium [177Lu] oxodotreotide): Power Against Progression

The LUTATHERA® brochure offers a succinct summary of the clinical evidence supporting the effectiveness and well-understood safety profile of LUTATHERA® in the management of GEP-NETs in adults. It presents the key progression-free survival and objective response rate data for LUTATHERA® and describes its impact on patient quality of life, as well as presenting its toxicity profile. It also provides a concise overview of recommended treatment regimen and the consensus guideline recommendations from the European Neuroendocrine Tumour Society (ENETS).

AAA-Lu177-UK-2173 | December 2023

Ask Speakers


Medical Information Request